JBC Avanti Polar Lipids

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Felding-Habermann, B.
Right arrow Articles by Ruggeri, Z. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Felding-Habermann, B.
Right arrow Articles by Ruggeri, Z. M.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Volume 271, Number 10, Issue of March 8, 1996 pp. 5892-5900
©1996 by The American Society for Biochemistry and Molecular Biology, Inc.
Role of 3 Integrins in Melanoma Cell Adhesion to Activated Platelets under Flow (*)

(Received for publication, August 3, 1995; and in revised form, January 2, 1996)

Brunhilde Felding-Habermann (§), ,  Rolf Habermann ,  Enrique Saldívar ,  Zaverio M. Ruggeri

From the The Scripps Research Institute, Department of Molecular and Experimental Medicine, La Jolla, California 92037

ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
FOOTNOTES
ACKNOWLEDGEMENTS
REFERENCES

ABSTRACT

Mechanisms mediating tumor cell attachment to the vessel wall under flow conditions are largely unknown. Therefore we analyzed the ability of human melanoma cells to adhere to an immobilized matrix during blood flow and determined the role of platelets in this process. In a parallel plate flow chamber, M21 melanoma cells were suspended in human blood and perfused over a collagen I matrix at a wall shear rate of 50 s (2 dynes/cm^2) to simulate venous flow over a thrombogenic surface. Melanoma cell interaction with the matrix or blood cells and platelets was monitored and quantified by fluorescence and confocal laser microscopy. Despite their ability to adhere to collagen I under static conditions, M21 cells failed to attach directly to this matrix during blood flow. However, they associated with adherent thrombi, and this resulted in stable melanoma cell arrest. Inhibition of platelet activation or platelet integrin alphaIIbbeta3 function abolished M21 cell attachment. Melanoma cell interaction with thrombi was specific and required beta3 integrin expression. M21-L cells which lack integrin alphavbeta3 failed to associate with thrombi and to arrest during blood flow. Transfection of these cells with the integrin subunits alphav or alphaIIb resulted in variants expressing alphavbeta3, as in the wild type, or alphaIIbbeta3. Both variants were able to associate with thrombi and to arrest during blood flow. Therefore, beta3 integrin-mediated binding to activated platelets represents an efficient mechanism for melanoma cell arrest under flow, and this may contribute to the role of platelets in hematogenous metastasis.

INTRODUCTION

During metastasis, tumor cells disseminate to distant organs via the lymph or the blood stream(1) . The arrest of metastasizing tumor cells within the blood stream is a prerequisite for their extravasation. This step is rate-limiting during hematogenous metastasis. In the blood stream, tumor cells are exposed to flow-dependent shear forces, plasma proteins, blood cells, and platelets, all of which may affect tumor cell survival, arrest, and extravasation. Mechanisms which mediate tumor cell arrest involve adhesive interactions of tumor cells with vascular cells and their matrices. A major limitation of our current knowledge of such adhesive interactions originates from the fact that most experimental models used for their study are based on static conditions that are different from those present in the vasculature. Specifically, effects generated by blood flow and the resulting shear forces may critically affect adhesive cell interactions(2) . Therefore, the goal of the present study was to analyze tumor cell arrest under flow conditions. This was achieved by using an in vitro model that mimics flow in the vasculature. The system is based on a parallel plate flow chamber combined with confocal laser microscopy and real time recording to document and quantify tumor cell adhesive properties under flow.

Tumor cells originating from solid tumors express a variety of adhesion receptors which support their attachment to extracellular matrices present in tissues and the vessel wall, such as collagen, fibrin, fibronectin, laminin, vitronectin, and von Willebrand factor(3) . Adhesion receptors also participate in tumor cell interactions with the intact endothelium of the vasculature. This has been demonstrated mostly under static conditions, and many of these adhesion receptors were identified as members of the integrin family including beta1 integrins containing the alpha subunits alpha1, alpha2, alpha3, alpha4, alpha5, alpha6, alpha7, and the alphav integrins alphavbeta3 and alphavbeta5(4) . Static conditions are, however, unlikely to occur in the blood stream. It has been suggested that passive entrapment of tumor cells in narrow capillary vessels may favor their attachment to the endothelium or exposed sites of the subendothelial matrix via adhesion receptors genuine to the tumor cells. Yet shear conditions can reach maximal levels in capillary passages(5) . Therefore, adhesion mechanisms mediating tumor cell attachment to the vessel wall would have to be designed such that adhesive interactions can be established under flow conditions and continuously withstand shear stress. While mechanisms for flow-resistant adhesion have been identified for platelets as well as for leukocytes and enable them to fulfill their specific functions during hemostasis and inflammation(6, 7) , it is yet unknown whether metastasizing tumor cells possess similar mechanisms. It has long been thought that platelets may assist hematogenous dissemination of metastasizing cells(8, 9, 10) . Perhaps the most convincing evidence is the inhibition of metastasis by experimental thrombocytopenia shown for a variety of tumors(11, 12, 13, 14) . We therefore hypothesized that tumor cells may interact with platelets and thereby acquire specific mechanisms which mediate platelet anchorage under flow. To test this hypothesis we selected a human melanoma cell model, because melanoma is the most malignant form of skin cancer characterized by a high frequency of metastasis during early stages of the disease. M21 melanoma cells suspended in human blood failed to attach directly to a collagen I matrix under flow, even at a relatively low wall shear rate of 50 s (2 dynes/cm^2) which corresponds to venous blood flow(5) . However, the melanoma cells were able to associate with attached platelets that had become activated and engaged in thrombus formation due to their initial matrix contact. The interaction between melanoma cells and platelets resulted in stable melanoma cell arrest during continued blood flow. The association between melanoma cells and platelets was not due to passive entrapment but was identified as a specific, receptor-mediated interaction involving beta3 integrin function on both the melanoma cells and the platelets. Thus, our results demonstrate that melanoma cell arrest to a matrix during blood flow can be mediated by their specific interaction with platelets which establish the initial matrix contact.

MATERIALS AND METHODS

Antibodies

Integrin-specific mAbs LJ-CP8 (function blocking anti-alphaIIbbeta3)(15) , LM 609 (anti-alphavbeta3) (16) (generous gift from Dr. D. Cheresh, The Scripps Research Institute, La Jolla, CA), 12F1 (anti-alpha2beta1) (17) (generous gift from Dr. V. Woods, University of California San Diego, San Diego, CA), AV-8 (anti-alphav), and AV-10 (anti-beta3) were affinity-purified from ascites on protein A-Sepharose (Pharmacia Biotech Inc.). mAbs (^1)AV-8 and AV-10 were generated by immunizing mice with alphavbeta3 protein from human placenta. Purification of alphavbeta3 was carried out as described elsewhere(18) . The specificity of the antibodies was determined by testing their reactivity with purified alphavbeta3 or alphaIIbbeta3 receptor protein (the latter was a generous gift from Dr. T. Kunicki, The Scripps Research Institute, La Jolla, CA) by enzyme-linked immunosorbent assay and Western blot, as well as by flow cytometry using human platelets or human tumor cells known to express alphavbeta3 or other alphav integrins.

Cells and Culture

M21 human melanoma cells were used with permission of Dr. D. L. Morton (University of California, Los Angeles, CA). M21-L cells lacking alphav integrin expression were used with permission of Dr. D. Cheresh (The Scripps Research Institute, La Jolla, CA)(16) . M21-L4 cells derived from M21-L cells were transfected with alphav to reconstitute alphav integrin expression. M21-L4 cells and the adhesive functions of M21, M21-L, and M21-L4 cells under static conditions were described earlier(19) . M21-LIIb cells were generated by transfecting M21-L cells with a full-length cDNA encoding human alphaIIb cloned into vector DNA pcDNA1neo (Invitrogen, San Diego, CA) using the Lipofectin protocol (Life Technologies, Inc.). In brief, subconfluent adherent cells were incubated with 2 µg of cDNA and 40 µg of Lipofectin for 12 h and allowed to recover for 48 h before selection in neomycin for 3 wk at a concentration of 1 mg/ml. Neomycin-resistant cells were expanded and enriched for alphaIIbbeta3 expression by repetitive fluorescence-activated cell sorting using alphaIIbeta3 complex specific mAb LJ-CP8. All cells were grown in DMEM with 10% fetal bovine serum, 20 mM Hepes, 1 mM pyruvate, and tested free from mycoplasma during these studies.

Blood Drawing and Anticoagulant

Human blood was drawn by venipuncture from healthy volunteers into PPACK (H-D-Phe-Pro-Arg-chloromethyl ketone hydrochloride, Bachem Bioscience Inc., Philadelphia, PA) at 50 nM final concentration. PPACK inhibits thrombin function and was chosen as anticoagulant because it does not interfere with platelet activation or cation-dependent platelet aggregation. In cases where inhibition of platelet activation was desired, blood was drawn into PPACK plus 20 nM final concentration of prostaglandin E(1) (PGE(1)).

Preparation of Washed Blood

Human blood containing 50 nM PPACK and 5 units/ml ADP scavenger apyrase (Sigma) was centrifuged at 2500 times g for 15 min at room temperature. Plasma was removed and replaced with an equivalent volume of HEPES-Tyrode buffer, pH 6.5 (10 mM HEPES, 140 mM NaCl, 2.7 mM KCl, 0.4 mM NaH(2)PO(4), 10 mM NaHCO(3), and 5 mM dextrose) containing 1 unit/ml apyrase. The resuspended blood cells were centrifuged again at 2250 times g for 10 min. Washing of the blood cells was repeated two more times using HEPES-Tyrode buffer as above but containing only 0.2 unit/ml apyrase and finally no apyrase. The final pellet was reconstituted in HEPES-Tyrode buffer, pH 7.4, containing 50 mg/ml bovine serum albumin and 1 mM CaCl(2)(20) .

Staining of Cells and Blood for Flow Studies

A simple staining system was developed to distinguish melanoma cells from blood cells or platelets and to identify the cellular components of attached heteroaggregates. Melanoma cells were suspended in plain DMEM at 2 times 10^6 cells/ml and stained with hydroethidine (Polysciences, Inc., Warrington, PA) at 20 µg/ml final concentration for 30 min at 37 °C and then washed twice to remove excess dye. Hydroethidine intercalates into the DNA resulting in red fluorescent labeling of the cells. Prestained melanoma cells were suspended in human blood containing 10 µM mepacrine (quinancrine dihydrochloride; Sigma) which concentrates in cell cytoplasmic granules and platelet dense granules. Thus all cells and platelets in the suspension acquired a green fluorescence while the melanoma cells could be identified by their unique red fluorescence. Filter settings at 488/515 nm (excitation/emission) for mepacrine and at 543/590 nm for hydroethidine allowed differential detection of melanoma cells in the presence of whole blood. The hydroethidine signal was detected at lower intensity with the mepacrine filter settings; however, the hydroethidine filter settings almost completely excluded the mepacrine signal. Therefore, melanoma cells could be identified within heterogenous cellular structures. Erythrocytes were not visible in the fluorescent field due to the quenching effect of hemoglobin. Neither of the dyes, hydroethidine or mepacrine, impaired cell adhesive functions as was tested in stationary assays.

Preparation of Collagen I Matrix and Flow Chamber Assembly

Suspensions of fibrillar collagen I (bovine Achilles tendon, Sigma) were prepared as described earlier(21) . In brief, 2 mg/ml collagen I from bovine Achilles tendon (Sigma) was suspended in 0.5 M acetic acid, pH 2.8, homogenized at room temperature for 3 h, centrifuged at 1,000 rpm for 10 min, and stored at 4 °C. For matrix preparation, glass coverslips (no. 1, 24 times 50 mm, Corning Inc., Corning, NY) were coated with 200 µl of collagen suspension in a humid atmosphere for 1 h at room temperature. The coverslips were rinsed three times with DMEM prior to assembly of the flow chamber. The flow chamber consisted of the matrix-coated glass coverslip as the bottom which was placed onto a metal frame. A rectangular silicon gasket (250 µm thick) was placed onto the coverslip before mounting a 37 times 65 times 12-mm acrylic block as the top of the flow chamber. This block was secured to the frame by four screws and contained two 27-mm long and 4-mm wide drillings used as chamber inlet and outlet, respectively. The inner dimensions of the flow chamber were 14 times 28 times 0.2-mm(22) . The chamber was filled with DMEM and connected to a pump system via medium-filled silicon tubings before placing it onto the heated and enclosed stage of the microscope. All flow experiments were carried out at 37 °C. Based on the design of the flow chamber, a given flow rate generated a corresponding wall shear rate which was constant throughout the chamber. The relationship between the wall shear rate (∂/∂z) (velocity gradient evaluated at the wall) and shear stress is ∂/∂z = /µ, where is the velocity of the fluid, z is the distance to the surface, is the fluid shear stress, and µ is the fluid viscosity. The shear rate (∂/∂z) has the dimension s(5) . This unit was used throughout the present studies to address the flow conditions used in the experiments.

Fluorescence and Confocal Laser Microscopy

The microscopy system used was specifically designed to visualize, record, and quantify the dynamics of cell-cell and cell matrix interactions during flow experiments. It consisted of an inverted microscope equipped with fluorescence and confocal laser modes (Axiovert 135, LSM 410, Zeiss, Oberkochem, Germany) and was controlled by a computer using LSM software (Zeiss). For real time analysis, cell adhesive events were monitored and recorded by a video camera using the fluorescence mode. To examine the three-dimensional topography of adherent cellular structures, optical sections of the specimens along the z axis were acquired using the confocal laser mode.

Image Acquisition and Quantitation of Cell Adhesion

Images were captured either directly during a flow experiment or from video tapes that had been recorded during the experiment. To classify attached objects, to determine their location along the x and y coordinates, to count objects, and to measure surface area coverage by attached objects, the images were processed using MetaMorph® image processing software (Universal Imaging Corp., West Chester, PA). To quantitate melanoma cell arrest, the hydroethidine-stained cells (1 times 10^7 in 1 ml of DMEM) were suspended in 3 ml of mepacrine-containing blood and perfused over the collagen I matrix at a wall shear rate of 50 s. Without interrupting the flow or changing the flow rate, the chamber was then perfused with 3% paraformaldehyde in phosphate-buffered saline, and images of predefined optical fields (255 times 255 µm^2 each) were captured as follows. We designed a computer program which directed the mobile stage of the microscope to 50 predefined x and y positions starting from a reference point. The program further controlled the acquisition of images. At each position, two images were captured using filter settings to detect red fluorescence (melanoma cells) or green fluorescence (platelets and leukocytes), respectively. From these images, attached melanoma cells were enumerated based on their unique red fluorescence, and thrombi were identified and counted based on their size and green fluorescence. To differentiate thrombus-associated from directly matrix-attached melanoma cells, the coordinates of the melanoma cells were determined and compared to those of thrombi. During or at the end of experimental runs, numerous attached objects which were identified as melanoma cell-containing thrombi using the fluorescence mode were routinely subjected to confocal z sectioning in order to verify their cellular composition (platelets and blood cells detected at 488 nm, melanoma cells at 543 nm). The area within which the 50 measuring fields were defined was 4 times 6.3 mm. This area was located 1 mm away from the inlet and 3 mm away from the lateral margins of the flow chamber. This location was kept constant and was arbitrarily chosen, acknowledging that platelets and leukocytes attached to, and melanoma cells began to associate with, adherent thrombi already within the immediate vicinity of the inlet and thus became depleted from the suspension which reached the measuring area.

Image Processing and Classification of Attached Objects

To describe the relationship of thrombus size and melanoma cell association with thrombi, attached objects were classified as single platelets, microthrombi, small thrombi, or large thrombi. For this purpose the images were processed as follows. The background intensity of each image was determined and subtracted in order to standardize images which were acquired during different experimental runs. For binarization, the threshold was set to a level where the binarized image resembled the original image best. This is an arbitrary process which requires that the chosen threshold level is kept constant throughout measurement of all images in order to allow a valid comparison of the measured areas. In each of 10 randomly chosen images, the surface area coverage of 30 single platelets was measured, and average surface areas were determined. Based on these measurements, the objects were classified as single platelets (1-70 pixels), micro thrombi (71-250 pixels), small thrombi (251-1000 pixels), or large thrombi (>1000 pixels) wherein the distinction between thrombus classes is arbitrary. The total area of one optical field corresponded to 215,384 pixels.

RESULTS

To test our hypothesis that platelets may assist melanoma cell arrest during blood flow, we initially tested whether the melanoma cells can stimulate and induce platelet aggregation by using the classical stir aggregometer approach. This is important because the activation state of platelets may be critical for platelet-melanoma cell interaction(10) . M21 cells (or their variants, as below) were added to human platelet-rich plasma from citrate-treated blood at final concentrations of 5 times 10^5, 1 times 10^6, or 5 times 10^6 cells/ml and in the absence of other stimulants. The melanoma cells failed to induce platelet aggregation under these conditions, whereas 2 µM ADP, as a control, did (data not shown). For this reason, and because we wanted to examine the role of platelets on melanoma cell arrest during blood flow at a low shear rate, we chose collagen type I as an experimental matrix. At a low wall shear rate of 50 s, corresponding to a venous shear rate, collagen I promotes platelet adhesion mediated by integrin alpha2beta1 (23) and this results in platelet stimulation (24) and thrombus formation(25) .

Time Course of Platelet Adhesion and Melanoma Cell Arrest

At a wall shear rate of 50 s, platelets readily attached to the collagen I matrix, initially as single platelets. Within the measuring area, microthrombi consisting of 2-10 platelets formed within the first minute of perfusion. Within the second minute, additional platelets attached to adherent microthrombi resulting in the formation of small thrombi which continued to grow larger in size with continued perfusion. Thrombus formation indicated that the attached platelets had become activated and this promoted platelet cohesion. M21 melanoma cells failed to interact with the matrix during the first 2 min of perfusion. After this initial period, immobilized M21 cells were detected, and this coincided with the appearance of larger size thrombi (Fig. 1). Analyzing the positions of arrested melanoma cells revealed that 93% or more of the attached M21 cells were associated with platelet-containing thrombi. Within the measured surface area, 36-49% of the counted large thrombi contained M21 melanoma cells. M21 cells which did not establish contact to a thrombus largely failed to anchor to the matrix. Analysis of the cellular composition and three-dimensional topography of melanoma cell-containing thrombi by confocal z sectioning under continued flow showed platelets in direct contact with the melanoma cells and revealed the presence of leukocytes in most of the analyzed thrombi. A representative example of a melanoma cell-containing thrombus is shown in Fig. 2. In the majority of cases, the melanoma cells were not in contact with the matrix but attached to underlying platelets, sometimes in the vicinity of leukocytes. The rare individually attached M21 cells which were not associated with thrombi adhered directly to the matrix. These data demonstrate that melanoma cells suspended in blood can interact with platelets and thereby associate with and become incorporated into thrombi under flow conditions. This interaction with platelets greatly promoted melanoma cell arrest on the matrix during blood flow. This result was confirmed by quantitation of thrombus-associated versus directly matrix-attached M21 cells at 50 predefined positions at the end of the experimental runs as shown in Fig. 3. Corresponding results were obtained in numerous experiments using blood from different donors.

Figure 1: Time course of platelet adhesion and M21 melanoma cell arrest on collagen I during blood flow. M21 cells (2.5 times 10^6/ml final) were suspended in whole human blood containing PPACK as anticoagulant. This suspension was perfused over a glass coverslip coated with collagen I at a constant wall shear rate of 50 s. Collagen I was chosen as matrix to ensure platelet adhesion and activation at this low shear rate. The melanoma cells were prestained with hydroethidine (red) and washed before their addition to blood which contained mepacrine (green). All cells and platelets in the suspension acquired a green fluorescence (filter setting 488/515 nm) (upper panels), while the melanoma cells could be identified by their unique red fluorescence (filter setting 543/590 nm) (lower panels). At each time point, images were captured with both filter settings at identical x and y coordinates. The bar in the lower right panel represents 10 µm. Locations of tumor cells within thrombi are indicated by (+) in the upper right panel.


Figure 2: Confocal z sections of an M21 melanoma cell arrested inside of an attached thrombus. Images of the z sections were captured using the confocal mode of the microscope under continued flow (experimental conditions as detailed in Fig. 1). Bottom sections are shown left; top sections, right. Numbers represent distances from the bottom surface of the flow chamber in micrometers. All cells and platelets were stained with mepacrine (top row) visualizing leukocytes and an M21 cell (top left), the M21 cell amid platelets (top middle), and the platelets on the surface of the thrombus (top right). The M21 cell was identified by its red fluorescence (bottom row). All images were acquired at identical x and y positions. The bar in the lower right panel represents 10 µm.


Figure 3: Requirement of platelet function for M21 melanoma cell arrest during blood flow. A, M21 cells (1 times 10^7 in 1 ml DMEM) were suspended in 3 ml of human blood and perfused over collagen I at a shear rate of 50 s in the absence or presence of 50 µg/ml of mAbs LJ-CP8 (function blocking anti-alphaIIbbeta3) or AV-10 (not blocking anti-beta3), both IgG1, or 20 nM prostaglandin E(1) (PGE1). Without interrupting the flow, the chamber was then perfused with 3% paraformaldehyde and attached melanoma cells or thrombi were quantified by using a computer program which directed the mobile stage of the microscope to 50 predefined positions and controlled capturing of images with filter settings for green (all cells and platelets) or red fluorescence (melanoma cells) at identical x and y positions. Attached melanoma cells were identified as thrombus-associated by analyzing their position coordinates on the ``green'' and ``red'' images of identical optical fields using MetaMorph® image processing software. Platelet thrombi were distinguished from adherent leukocytes or individually attached melanoma cells by their larger size. Frequent confocal sectioning along the z axis of attached objects during control runs revealed objects, typically counted as thrombi, as aggregates of platelets or heteroaggregates containing platelets, leukocytes and/or melanoma cells ( Fig. 2shows an example). Optical field dimensions were 255 times 255 µm^2. Each bar represents the mean number of attached objects in 50 predefined fields of triplicate runs ± S.D. The data presented were obtained on the same day using blood from one donor. Numbers of attached thrombi and dependent numbers of thrombus-associated melanoma cells varied slightly due to blood donor variability. Controls runs at the beginning and end of each session ensured unchanged performance of the blood samples throughout the experiment. B, images of representative optical fields captured with filter settings for mepacrine (green fluorescence, upper row) or hydroethidine (red fluorescence, lower row) each pair at identical x and y coordinates. The (+) signs in thrombi in the upper left panel indicate the locations of the arrested M21 cells (as shown in the lower left panel). The bar in the lower right panel represents 10 µm.


Requirement of Platelet Function for Melanoma Cell Arrest

To determine whether platelet activation and platelet integrin alphaIIbbeta3 function are required for melanoma cell-platelet interaction, we examined the effects of PGE(1) and anti-alphaIIbbeta3 on platelet-dependent M21 cell arrest during blood flow (Fig. 3). PGE(1) interferes with platelet activation. Thus, the formation of large thrombi in response to platelet attachment to collagen I was inhibited. The melanoma cells failed to establish stable interactions with individually attached platelets or microthrombi even though the surface area covered by single platelets and micro thrombi in the presence of PGE(1) accounted for 68% of the area covered by large thrombi in control runs. Inhibition of the platelet integrin alphaIIbbeta3 function by mAb LJ-CP8 does not interfere with platelet activation, but blocks thrombus formation because the antibody prevents fibrinogen binding to alphaIIbbeta3(15) . As in the case of PGE(1) treatment, M21 cells did not associate with platelets that were individually attached to the matrix and failed to form thrombi due to mAb LJ-CP8 treatment. In the presence of control antibody AV-10, which we developed against beta3 and which fails to block beta3 integrin function, platelet thrombus formation and melanoma cell association with thrombi leading to melanoma cell arrest were not significantly affected. In both cases of platelet inhibition, treatment with PGE(1) or LJ-CP8, M21 cell arrest was reduced to occasional cells which directly adhered to the matrix. Their numbers were comparable to those of M21 cells directly attached to matrix found in control runs in the absence of platelet inhibitors. This indicates that melanoma cell interaction with platelets is required for efficient melanoma cell arrest to a collagen I matrix during blood flow and that this interaction depends on platelet activation and thrombus formation.

Relationship between Thrombus Size and Melanoma Cell Arrest

To investigate the relationship between thrombus size and platelet-dependent melanoma cell arrest under flow, we examined the effect of increasing concentrations of anti-alphaIIbbeta3 on thrombus size and melanoma cell attachment (Fig. 4). At low anti-alphaIIbbeta3 concentrations (20 or 50 µg/ml), the numbers of adherent single platelets or micro thrombi were strongly increased, whereas the number of small thrombi was slightly decreased compared to untreated or mAb AV-10-treated controls. Formation of large thrombi was strongly inhibited even at the lowest anti-alphaIIbbeta3 concentration tested. At a higher concentration (100 µg/ml), anti-alphaIIbbeta3 inhibited any size of platelet thrombi. Like formation of large thrombi, platelet-dependent melanoma cell arrest was strongly inhibited at all antibody concentrations tested (Fig. 4). These results indicate that thrombus size affects melanoma cell arrest under flow. This is supported by the observations that, during the time course of flow experiments, M21 cell attachment coincided with the appearance of larger size thrombi and that, at the end of experimental runs, arrested M21 cells were found associated mostly with large thrombi.

Figure 4: Relationship between thrombus size and platelet-dependent melanoma cell arrest. M21 cells were suspended in human blood and perfused over collagen I as in Fig. 3in the absence or presence of increasing concentrations of mAbs LJ-CP8 (function blocking anti-alphaIIbbeta3) (box) or AV-10 (not blocking anti-beta3) (up triangle). For each experimental condition, images were captured with filter settings for green (all cells and platelets) or red fluorescence (melanoma cells) at 50 predefined positions. For quantitation of attached objects the images were binarized, and object classifiers were defined based on surface area coverage of individual platelets, micro thrombi containing two to five platelets, small thrombi, or large thrombi (1-70, 71-250, 251-1000, and >1000 pixels, respectively, the total measured area corresponded to 215,384 pixels) using MetaMorph® image processing software. Identification and quantitation of thrombus-associated melanoma cells were done as in Fig. 3. Each data point represents mean numbers ± S.D. of attached objects of each class in 50 images expressed as a percent of control. Controls were done in the absence of antibody at the same day at the beginning and at the end of the experiment using blood from the same donor. Note differences in the scaling of the y axes.


Requirement of beta3 Integrin Expression for Melanoma Cell-Platelet Interaction

Large thrombi that attached to the matrix may locally change the pattern of blood flow and thereby alter shear conditions in their vicinity. We therefore examined whether the observed association between melanoma cells and thrombi was specific or due to passive entrapment at sites of potentially altered altered flow fields. Specific association between the melanoma cells and platelets likely depends on a receptor-mediated adhesive interaction. We hypothesized that beta3 integrins might be involved, using a mechanism similar to that which governs platelet-platelet interaction in thrombus formation. M21 cells express integrin alphavbeta3 but not alphaIIbbeta3 (Fig. 5). To examine whether alphavbeta3 participates in M21 cell association with platelet thrombi during blood flow, we compared M21 cells to M21-L cells which lack alphav integrin expression(16) . To attribute differences in the adhesive capacities of M21 and M21-L cells to alphavbeta3 function, M21-L cells were transfected with alphav to reconstitute alphavbeta3 expression (M21-L4 cells)(19) . M21 wild type and its variants M21-L and M21-L4 expressed comparable levels of collagen receptor, integrin alpha2beta1 (Fig. 5). Under static conditions, the cells attached readily and equally well to collagen I(19) . In contrast, platelet-dependent melanoma cell arrest to collagen I during blood flow was reduced by 93% when using M21-L cells (alphavbeta3) compared to M21 wild type cells (alphavbeta3). Association with platelet thrombi and arrest under flow was fully restored in M21-L4 cells (alphavbeta3) as shown in Fig. 6. In contrast to platelet-dependent melanoma cell arrest, formation of large thrombi and occasional direct attachment of melanoma cells to the matrix under flow occurred independently of the M21 cell type used (Fig. 6). This indicates that the interaction of M21 cells with platelet containing thrombi during blood flow is specific and depends on integrin alphavbeta3 expression by the melanoma cells. The specificity of M21 cell association with thrombi was supported by confocal z sectioning of a large number of melanoma cell-containing thrombi. This analysis revealed that the sites of melanoma cell association at the thrombi were random and included the center, the top, and the sides of the thrombi regardless of their exposure to the direction of blood flow. Therefore, melanoma cell attachment to thrombi appeared to be independent of changes in the flow fields in the vicinity of thrombi.

Figure 5: Flow cytometric analysis of beta3 integrin or collagen receptor alpha2beta1 expression by M21, M21-L, M21-L4, or M21-LIIb melanoma cells. The cells were stained with mAbs LM 609 for alphavbeta3, 12F1 for alpha2beta1, AV-8 for alphav, AV-10 for beta3, or LJ-CP8 for alphaIIbbeta3, respectively, followed by anti-mouse fluorescein isothiocyante. The samples were analyzed in a Becton Dickinson FACScan.


Figure 6: Requirement of beta3 integrin expression for melanoma cell association with platelets and arrest during blood flow. M21 (alphavbeta3, alphaIIbbeta3), M21-L (beta3), M21-L4 (alphavbeta3, alphaIIbbeta3), or M21-LIIb (alphavbeta3, alphaIIbbeta3) cells were suspended in human blood and perfused over a collagen I matrix and attachment of large thrombi, or melanoma cells with or without thrombus association, was quantified as in Fig. 3. Each bar represents the number of attached objects in 50 predefined fields of multiple runs ± S.D. Bars for M21 cells correspond to the mean of six runs, two of which were each done at the same date as M21-L, M21-L4, or M21-LIIb, respectively. Bars for M21-L, M21-L4, or M21-LIIb represent triplicate runs.


During platelet aggregation and thrombus formation, interaction of platelets is mediated by integrin alphaIIbbeta3. To investigate whether expression of this integrin by melanoma cells supports their association with platelets, we transfected M21-L cells with alphaIIb, resulting in alphaIIbbeta3 expressing M21-LIIb cells (Fig. 5). M21-LIIb cells associated with platelet thrombi during blood flow, and this mediated their arrest to the matrix to an extent comparable to that found for the alphavbeta3-expressing M21 or M21-L4 cells (Fig. 6). Platelet-dependent arrest of both M21-L4 and M21-LIIb cells was blocked by platelet inhibition through treatment with PGE(1) or anti-alphaIIbbeta3 mAb LJ-CP8, corresponding to the data shown for M21 wild type cells in Fig. 3. This indicates that beta3 integrin expression by melanoma cells supports their interaction with platelets under flow and may suggest that the mechanism involved is related to that of platelet-platelet interaction.

Requirement of Plasma Proteins for Platelet-mediated Melanoma Cell Arrest

To analyze whether plasma proteins are required for platelet-mediated melanoma cell arrest during blood flow, we tested the ability of M21 cells to attach to matrix-bound platelets in washed blood preparations. When M21 cells were suspended in washed blood cells reconstituted with buffer and perfused over a collagen I matrix at a wall shear rate of 50 s , platelet-mediated melanoma cell arrest was inhibited by 90%, and the surface area coverage by large thrombi was reduced by 94% as compared to whole, untreated blood (Fig. 7). The overall surface area coverage by platelets still accounted for 62% of that measured in whole blood since single platelets, micro and small thrombi made up 95% of total platelet coverage in washed blood cell suspensions, but only 53% in whole blood. These results indicate that platelet-mediated melanoma cell arrest largely depended on the presence of plasma proteins, which were required for the formation of large thrombi. This is in agreement with the above findings which showed that inhibition of large thrombus formation by other means, such as blocking platelet activation or platelet integrin alphaIIbbeta3 function, also resulted in the loss of melanoma cell arrest under flow. In order to test whether the platelets in the washed blood preparation had retained their ability to become activated and to aggregate, these platelets were analyzed in the aggregometer. The platelets underwent shape change and aggregated in response to 20 µM ADP and 1 mg/ml exogenous fibrinogen, albeit not to the full extent as measured in whole, untreated blood (data not shown). Furthermore, platelet-mediated melanoma cell arrest and large thrombus formation during blood flow over collagen I at 50 s were partially restored when fibrinogen was added to the washed blood preparation (Fig. 7).

Figure 7: Requirement of plasma proteins for platelet mediated melanoma cell arrest during blood flow. M21 melanoma cells were suspended in either plasma depleted, washed blood (open bars), washed blood containing 2 mg/ml human fibrinogen (light gray bars), or untreated whole blood (gray bars). The suspensions were perfused over a collagen I matrix at a wall shear rate of 50 s. Melanoma cell attachment and their association with thrombi was measured as in Fig. 3. Surface area coverage by platelets or thrombi of various sizes was determined as in Fig. 4. Each bar represents the mean numbers of pixels (± S.D., n = 3 runs using the same blood and washed blood preparation) for the surface coverage of attached objects as classified in Fig. 4or the numbers of arrested tumor cells at 50 predefined positions. Washed blood was prepared as detailed under ``Materials and Methods.''


DISCUSSION

This study was designed to analyze the ability of human melanoma cells to adhere to an immobilized matrix during blood flow and to determine the role of platelets in this process. This is pertinent to tumor metastasis because tumor cell arrest within the vasculature is required for extravasation and thus limits the metastatic capacity of tumor cells that disseminate via the blood stream. In this report we provide evidence that efficient melanoma cell arrest to a collagen I matrix during blood flow depends on the interaction of the melanoma cells with platelets which have already established matrix contact. Despite their ability to adhere to collagen I under static conditions in an integrin alpha2beta1-dependent manner(19) , M21 human melanoma cells largely failed to attach directly to this matrix during blood flow. They were, however, able to associate with platelets, and this interaction resulted in M21 cell arrest. The flow-resistant interaction of M21 cells and platelets depended on platelet activation and thrombus formation. Moreover, the interaction was found to be specific and required beta3 integrin function on both the melanoma cells and the platelets.

The ability of platelets to support tumor cell arrest during blood flow may contribute to the role of platelets in hematogenous metastasis. A number of reports indicate that interference with platelet function in vivo reduced tumor metastasis in animal models. Moreover, reduction of platelet counts inhibited metastasis of a variety of tumor cells including melanomas, carcinomas, and sarcomas(11, 12, 13, 14) . In these cases, metastasis was reduced regardless of the ability of the tumor cells to induce platelet aggregation in vitro(26, 27, 28) . Tumor cells can induce platelet aggregation by releasing ADP(29, 30, 31, 32, 33) , generating tissue factor(34) , or by other mechanisms leading to thrombin formation(35, 36, 37) . It is conceivable that two distinct mechanisms are involved in platelet-assisted tumor cell arrest in the vasculature: first, an induction of platelet activation and aggregation by tumor cells or their released factors which is possibly accompanied by passive entrapment of tumor cells in platelet aggregates; and second, a specific adhesive interaction between platelets and tumor cells. Both types of interaction may allow tumor cells to utilize indirectly the platelet-specific mechanisms for successful adhesion during blood flow. Since M21 melanoma cells failed to induce platelet activation in vitro, we sought to define conditions for their local exposure to stimulated platelets. Therefore, we chose collagen I as the matrix because it represents a thrombogenic surface and promotes platelet adhesion and thrombus formation at low shear rates, corresponding to venous blood flow(23, 24, 25) . Although collagen I is present in the vessel wall, it becomes exposed to blood only in deep vessel injury or upon rupture of atherosclerotic plugs(38, 39) . Metastasizing cells are unlikely to encounter this matrix in the vasculature. Therefore, collagen I was used in this study solely as a model for a thrombogenic surface. The collagen I matrix was perfused with M21 melanoma cells suspended in whole human blood. It has to be considered that plasma contains collagen-binding proteins, such as fibronectin, von Willebrand factor, or vitronectin(40) , which potentially modified the matrix during the experiments. However, it has been reported that a function-blocking antibody to the alpha2 subunit of the platelet collagen receptor alpha2beta1 fully inhibited platelet adhesion to collagen I during perfusion with whole blood at wall shear rates up to 1600 s(41) . Other investigators showed that at wall shear rates of 1500 s or higher, von Willebrand factor immobilized to the collagen I matrix during blood flow becomes the relevant adhesive ligand for platelets, since a recombinant fragment of von Willebrand factor, von Willebrand factor 445-733 containing the binding site for platelet receptor GPIb, significantly inhibited platelet attachment at geq1500 s but not at lower shear rates(42) . In agreement with these findings, platelet adhesion, thrombus formation, and platelet-mediated melanoma cell arrest during blood flow over collagen I at 50 s in our experiments were not significantly affected by the presence of mAb LJ Ib-1 which blocks GPIb function (data not shown). Together, this suggests that collagen remained the major matrix component for platelet adhesion at the low shear rate used in our experiments. A possible modification of the collagen matrix did not improve platelet-independent melanoma cell attachment even after prolonged periods of blood flow.

The association of M21 melanoma cells with platelets under flow depended on platelet activation and thrombus formation since PGE(1) or anti-alphaIIbbeta3 abolished M21 cell interaction with platelets. In the presence of these inhibitors, attachment of individual platelets and micro thrombi was strongly enhanced; however, they failed to support M21 cell adhesion. The increase in single platelet and micro thrombus attachment in the presence of platelet inhibitors may be explained by the fact that platelets were not depleted from the streaming blood due to incorporation into large thrombi as observed in the absence of platelet inhibitors. Association of M21 cells with thrombi coincided with the occurrence of large size thrombi. Detailed analyses of mural thrombogenesis revealed that the blood flow pattern in the vicinity of growing thrombi is characterized by standing vortices that develop upstream and downstream of the thrombi. This leads to considerably reduced velocities in and near the recirculating regions which in turn permit the local accumulation of platelet-activating agents that are released or induced by the aggregating platelets within the thrombi(43) . It is therefore plausible that tumor cells may be passively trapped close to or between nearby growing thrombi. We have ruled out that the M21 melanoma cell interaction with thrombi during blood flow was due to nonspecific entrapment. We found melanoma cells associated with thrombi at random sites, indicating that changes in flow did not affect the interaction. Moreover, we demonstrated that the M21 cell association with thrombi was a specific, receptor-mediated process. Failure of M21 cells to bind to adhered platelets in which the integrin alphaIIbbeta3 function had been blocked suggests that alphaIIbbeta3 participates in the interaction between platelets and melanoma cells. This concept is supported by previous reports (44, 45) and is substantiated by the finding that platelets from Glanzmann's thrombasthenic patients, which lack alphaIIbbeta3 expression, failed to interact with tumor cells in vitro(46) . In order to identify a potential counter receptor for platelet integrin alphaIIbbeta3 expressed by the melanoma cells, we reasoned that alphaIIbbeta3 may bind to a related receptor expressed by the melanoma cell using a mechanism similar to that which governs platelet-platelet interaction in thrombus formation. Evidence suggests that an alphaIIbbeta3-related integrin expressed by tumor cells might be involved in their interaction with platelets(46, 47) . This alphaIIbbeta3-related molecule may represent tumor cell integrin alphavbeta3, since these receptors share characteristic homologies and a ligand recognition repertoire. In order to examine the role of melanoma cell integrin alphavbeta3, we utilized an M21 cell variant that lacks alphavbeta3 expression (M21-L) (16) in comparison to a variant in which alphavbeta3 expression was reconstituted upon transfection (M21-L4)(19) . Using this system, we demonstrated that alphavbeta3 expression was required for M21 cell association with platelets, and that this resulted in efficient M21 cell arrest on a collagen I matrix during blood flow.

In human melanoma, expression of alphavbeta3 was found to be restricted to the metastatic phenotype (48) and to commence with the onset of vertical growth within the primary lesion(49) . Furthermore, we have evidence that alphavbeta3 contributes to the tumorigenicity of human melanoma cells (19) and to adhesive interactions with fibrin(ogen) and its breakdown products which occur in the tumor stroma(50) . Thus, melanoma cell alphavbeta3 seems to be involved in early stages of tumor development. We now provide evidence suggesting that this adhesion receptor may also be involved in later stages of melanoma progression by contributing to melanoma cell-platelet binding and arrest during blood flow.

It is yet unknown whether platelet binding to the melanoma cells is based on a direct interaction between the two cell types or whether bridging ligands are involved. We hypothesize that platelet integrin alphaIIbbeta3 and melanoma cell integrin alphavbeta3 interact via divalent or multivalent RGD-containing plasma proteins, such as fibrinogen, von Willebrand factor, fibronectin, or thrombospondin. This concept is supported by a number of reported inhibition studies. Antibodies directed to either platelet alphaIIbbeta3 or to its ligands, as well as RGD-containing peptides and snake venoms, significantly reduced the interaction between tumor cells and platelets in vitro and metastasis in vivo(14, 44, 51, 52, 53, 54, 55, 56, 57) . The antimetastatic activity of RGD peptides was associated with an accelerated disappearance of isotope-labeled tumor cells from the lungs of treated mice. This indicates that specific adhesion processes were involved in stable tumor cell arrest in the lung capillaries. To address the question whether plasma proteins, envisaged as containing adhesive ligands for the beta3 integrins, were required for platelet-mediated melanoma cell arrest during blood flow, we depleted the plasma proteins from blood by repeated washes. As expected, platelet adhesion to the collagen I matrix was not impaired; however, the formation of large size thrombi was drastically reduced, and consequently, platelet-mediated melanoma cell adhesion was also inhibited. Thrombus formation and melanoma cell arrest were partially restored in the presence of added fibrinogen. The lack of a full recovery of thrombus formation and melanoma cell arrest could be due to one or both of the following reasons. First, platelets as well as leukocytes become refractory during the blood-washing procedure, and second, other plasma proteins, such as fibronectin, von Willebrand factor, vitronectin, or thrombospondin, may be involved in addition to fibrinogen. Together, our results indicate that plasma protein(s) are required for platelet-mediated melanoma cell arrest under our experimental conditions. Logically, the mechanism of melanoma cell-platelet heteroaggregate formation needs to be addressed in greater detail, employing experimental procedures which involve minimal disturbance of platelet responsiveness.

Integrin alphaIIbbeta3 mediates platelet cohesion via fibrinogen and/or von Willebrand factor as major bridging ligands in thrombus formation. Therefore, we sought to compare beta3 integrins alphavbeta3 and alphaIIbbeta3 expressed by the same type of melanoma cell for their potential to mediate melanoma cell interaction with platelets. To accomplish this, we transfected M21-L cells with alphaIIb by a method similar to that described by Kieffer et al.(58) , resulting in the M21-LIIb variant which expresses alphaIIbbeta3 but not alphavbeta3. Several reports suggest that integrin alphaIIbbeta3 may be expressed by certain tumor cells(59) . M21-LIIb cells were able to associate stably with platelet-containing thrombi and utilized this mechanism for efficient arrest during blood flow. The extent of M21-LIIb cell interaction with platelets was comparable to that found using alphavbeta3-expressing M21 or M21-L4 cells. This indicates that beta3 integrins in general can function as receptors on melanoma cells during their interaction with platelets. This finding may lend further support to the concept that the mechanism involved in melanoma cell-platelet interaction is related to that which governs platelet cohesion in thrombus formation.

We propose that beta3 integrin-mediated tumor cell-platelet interaction may represent one possible mechanism to facilitate hematogenous dissemination of tumor cells. It is yet unknown whether platelets promote tumor cell arrest on intact endothelium, a process which may involve more than one receptor. These may include other integrins and selectins, the latter of which could contribute to the initial binding events(60, 61, 62, 63, 64, 65) . Among the integrins, alpha4beta1 represents an example for supporting leukocyte rolling on and attachment to endothelial cells under flow(66, 67) . alpha4beta1 is expressed by a variety of tumor cells including certain melanoma cells, and it may be involved in the melanoma cell interaction with the vascular endothelium. alpha5beta1 and alphav integrins were shown to support tumor cell arrest under flow to fibronectin or vitronectin substrates(68) . Stabilization of the initial binding events seemed to depend on the activity of transglutaminase expressed by the tumor cells(69) . Under our experimental conditions, one likely candidate to contribute to melanoma cell interaction with thrombi is P-selectin. P-selectin is expressed by activated platelets and was shown to mediate tumor cell-platelet binding under stationary conditions(70) . Under flow conditions, P-selectin has been reported to support leukocyte rolling. In our flow experiments, we recorded adhesive events in real time and found no evidence of melanoma cell rolling. A monoclonal antibody directed to human P-selectin, known to block P-selectin-mediated interactions, such as adherence of activated platelets to neutrophils (71) or histamine-induced rolling of leukocytes in postcapillary venules(72) , failed to interfere with platelet-mediated melanoma cell arrest under our experimental conditions (data not shown). A more detailed analysis of the initial binding events between activated platelets and melanoma cells during blood flow will reveal a potential contribution of P-selectin. In vivo, association of platelets with tumor cells attached to vascular endothelium has been reported (73) and suggests that platelets may stabilize and protect attached tumor cells during blood flow. In vivo studies will help to clarify whether beta3 integrin-mediated tumor cell-platelet interaction contributes to the complex process of tumor cell arrest in the vasculature.

FOOTNOTES

*
This work was supported by National Institutes of Health Grant CA67988-01. This is manuscript no. 9437-MEM of The Scripps Research Institute. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore by hereby marked ``advertisement'' in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

§
To whom correspondence should be addressed: The Scripps Research Institute, Dept. of Molecular and Experimental Medicine, Maildrop SBR 8, 10666 North Torrey Pines Rd., La Jolla, CA 92037. Tel.: 619-554-8195 or 8950; Fax: 619-554-6779.

(^1)
The abbreviations used are: mAb, monoclonal antibody; DMEM, Dulbecco's modified Eagle's medium; PGE(1), prostaglandin E(1).

ACKNOWLEDGEMENTS

We thank Drs. D. A. Cheresh (The Scripps Research Institute, La Jolla) for mAb LM 609, V. Woods (University of California, San Diego) for mAb 12F1, L. Phillips (Cytel, La Jolla) for the anti P-selectin antibody, and Drs. B. Mueller, R. A. Reisfeld, and D. R. Salomon for critically reading this manuscript.

REFERENCES

  1. Fidler, I. J. (1990) Cancer Res. 50, 6130-6138 [Abstract/Free Full Text]
  2. Weiss, L., and Schmid-Schoenbein, G. W. (1989) Cell Biophys. 14, 187-215 [Medline] [Order article via Infotrieve]
  3. Timpl, R. (1989) Eur. J. Biochem. 180, 487-502 [Medline] [Order article via Infotrieve]
  4. Ruoslahti, E., and Giancotti, F. G. (1989) Cancer Cells 1, 119-126
  5. Whitmore, R. L. (1968) Rheology of the Circulation , pp. 90-133, Pergamon Press, Oxford
  6. Ruggeri, Z. M., and Ware, J. (1993) FASEB J. 7, 308-316 [Abstract]
  7. Smith, C. W. (1993) Semin. Hematol. 30, Suppl 4, 45-53
  8. Jamieson, G. A., Bastida, E., and Ordinas, A. (1987) in Platelets in Biology and Pathology , Vol. III (MacIintyre, D. E., and Gordon, J. L., eds) pp. 161-189, Elsevier/North Holland, Amsterdam
  9. Honn, K. V., Tang, D. G., and Chen, Y. Q. (1992) Semin. Thromb. Hemostasis 18, 392-415 [Medline] [Order article via Infotrieve]
  10. Honn, K. V., Tang, D. G., and Crissman, J. D. (1992) Cancer Metastasis Rev. 11, 325-351 [CrossRef][Medline] [Order article via Infotrieve]
  11. Gasic, G. J., Gasic, T. B., Galanti, N., Johnson, T., and Murphy, S. (1973) Int. J. Cancer 11, 704-718 [Medline] [Order article via Infotrieve]
  12. Kimoto, M., Ando, K., Koike, S., Matsumoto, T., Jibu, T., Moriya, H., and Kanegasak, S. (1993) Clin. Exp. Metastasis 11, 285-292 [CrossRef][Medline] [Order article via Infotrieve]
  13. Costantini, V., Fuschiotti, P., Giampietri, A., Allegrucci, M., Agnelli, G., Neci, G. G., and Fioretti, M. C. (1990) Prostaglandins 39, 581-599 [CrossRef][Medline] [Order article via Infotrieve]
  14. Karpatkin, S., Pearlstein, E., Ambrogio, C., and Coller, B. S. (1988) J. Clin. Invest. 81, 1012-1019
  15. Niiya, K., Hodson, E., Byers-Ward, V., Koziol, J. A., Plow, E. F., and Ruggeri, Z. M. (1987) Blood 70, 475-483 [Abstract/Free Full Text]
  16. Cheresh, D. A., and Spiro, R. C. (1987) J. Biol. Chem. 262, 17703-17711 [Abstract/Free Full Text]
  17. Pischel, K. D., Bluestein, H. G., and Woods, V. L., Jr. (1988) J. Clin. Invest. 81, 505-513
  18. Smith, J. W., and Cheresh, D. A. (1988) J. Biol. Chem. 263, 18726-18731 [Abstract/Free Full Text]
  19. Felding-Habermann, B., Mueller, B. M., Romerdahl, C. A., and Cheresh, D. A. (1992) J. Clin. Invest. 89, 2018-2022
  20. Goto, S., Salomon, D. R., Ikeda, Y., and Ruggeri, Z. M. (1995) J. Biol. Chem. 270, 23352-23361 [Abstract/Free Full Text]
  21. Folie, B. J., McIntire, L. V., and Lasslo, A. (1988) Blood 72, 1393-1400 [Abstract/Free Full Text]
  22. Hubbell, J. A., and McIntire, L. V. (1986) Biomaterials 7, 354-363 [CrossRef][Medline] [Order article via Infotrieve]
  23. Kunicki, T. J., Nugent, D. J., Staats, S. J., Orchekowski, R. P., Wayner, E. A., and Carter, W. G. (1988) J. Biol. Chem. 263, 4516-4519 [Abstract/Free Full Text]
  24. Brass, L. F., and Bensusan, H. B. (1974) J. Clin. Invest. 54, 1480-1487
  25. Baumgartner, H. R., Muggli, R., Tschopp, T. B., and Turitto, V. T. (1976) Thromb. Haemostasis 35, 124-138 [Medline] [Order article via Infotrieve]
  26. Gasic, G. J. (1984) Cancer Metastasis Rev. 3, 99-116 [CrossRef][Medline] [Order article via Infotrieve]
  27. Tang, D. G., Onoda, J. M., Steinert, B. W., Grossi, I. M., Nelson, K. K., Umbarger, L., Diglio, C. A., Taylor, J. D., and Honn, K. V. (1993) Int. J. Cancer 54, 338-347 [Medline] [Order article via Infotrieve]
  28. Tzanakakis, G. N., Agarwal, K. C., and Vezeridis, M. P. (1993) Cancer 71, 2466-2471 [CrossRef][Medline] [Order article via Infotrieve]
  29. Holme, R., Oftebro, R., and Hovig, T. (1978) Thromb. Haemostasis 40, 89-102 [Medline] [Order article via Infotrieve]
  30. Grignani, G., and Jamieson, G. A. (1988) Blood 71, 844-849 [Abstract/Free Full Text]
  31. Bastida, E., and Ordinas, A. (1988) Haemostasis 18, 29-36 [Medline] [Order article via Infotrieve]
  32. Grignani, G., Pacchiarini, L., Ricetti, M. M., Dionigi, P., Jemos, V., Zucchella, M., and Fratino, P. (1989) Invasion Metastasis 9, 298-309 [Medline] [Order article via Infotrieve]
  33. Longenecker, G. L., Beyers, B. J., Bowen, R. J., and King, T. (1989) Cancer Res. 49, 16-19 [Abstract/Free Full Text]
  34. Bastida, E., Ordinas, A., Escolar, G., and Jamieson, G. A. (1984) Blood 64, 177-184 [Abstract/Free Full Text]
  35. Tohgo, A., Tanaka, N. G., and Ogawa, H. (1985) Invasion Metastasis 5, 96-105 [Medline] [Order article via Infotrieve]
  36. Esumi, N., Fan, D., and Fidler, I. J. (1991) Cancer Res. 51, 4549-4556 [Abstract/Free Full Text]
  37. Cavanaugh, P. G., Sloane, B. F., and Honn, K. V. (1988) Haemostasis 18, 37-46 [Medline] [Order article via Infotrieve]
  38. Timpl, R. (1993) Experientia 49, 417-428 [CrossRef][Medline] [Order article via Infotrieve]
  39. Barnes, M. J. (1985) Collagen Relat. Res. 5, 65-97
  40. Paulsson, M. (1992) Crit. Rev. Biochem. Mol. Biol. 27, 93-127 [Medline] [Order article via Infotrieve]
  41. Saelman, E. U. M., Nieuwenhuis, H. K., Hese, K. M., de Groot, P. G., Heijnen, H. F. G., Sage, E. H., Williams, S., McKeown, L., Gralnick, H. R., and Sixma, J. J. (1994) Blood 83, 1244-1250 [Abstract/Free Full Text]
  42. Alevriadou, B. R., Moake, J. L., Turner, N. A., Ruggeri, Z. M., Folie, B. J., Phillips, M. D., Schreiber, A. B., Hrinda, M. E., and McIntire, L. V. (1993) Blood 81, 1263-1276 [Abstract/Free Full Text]
  43. Folie, B. J., and McIntire, L. V. (1989) Biophys. J. 56, 1121-1141 [Abstract/Free Full Text]
  44. Nierodzik, M. L., Plotkin, A., Kajumo, F., and Karpatkin, S. (1991) J. Clin. Invest. 87, 229-236
  45. Wojtukiewicz, M. Z., Tang, D. G., Ciarelli, J. J., Nelson, K. K., Walz, D. A., Diglio, C. A., Mammen, E. F., and Honn, K. V. (1993) Int. J. Cancer. 54, 793-806 [Medline] [Order arti